Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

© 2014 by the American Association for the Study of Liver Diseases. Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblas...

Full description

Saved in:
Bibliographic Details
Main Authors: Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean Frederic Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won Young Tak, Xiaoping Yu, Joon Hyeok Lee, Shi Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian B. Walters, Christine Dela Cruz, Valerie Poulart, Jian Hua Wang
Other Authors: Kindai University School of Medicine
Format: Article
Published: 2018
Subjects:
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/34875
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/34875

Similar Items